Paiella, S. et al. (2023) A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing. ESMO Open, 8(2), 100881. (doi: 10.1016/j.esmoop.2023.100881) (PMID:36822114) (PMCID:PMC10163165)

Patel, M. et al. (2022) Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer. British Journal of Cancer, 126(12), pp. 1704-1714. (doi: 10.1038/s41416-022-01729-2) (PMID:35173303) (PMCID:PMC9174220)

Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)

Ewing, A. et al. (2021) Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma. Clinical Cancer Research, 27(11), pp. 3201-3214. (doi: 10.1158/1078-0432.CCR-20-4068) (PMID:33741650) (PMCID:PMC7610896)

Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)

Dreyer, S. B. et al. (2021) Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology, 160(1), pp. 362-377. (doi: 10.1053/j.gastro.2020.09.043) (PMID:33039466) (PMCID:PMC8167930)

Morton, J. P. and Watt, D. M. (2021) Heterogeneity in the pancreatic cancer microenvironment – TGFβ as a master regulator? Cancers, 13(19), 4984. (doi: 10.3390/cancers13194984) (PMID:34638468) (PMCID:PMC8508541)

Beer, P. A., Cooke, S. L. , Chang, D. K. and Biankin, A. V. (2020) Defining the clinical genomic landscape for real-world precision oncology. Genomics, 112(6), pp. 5324-5330. (doi: 10.1016/j.ygeno.2020.10.032) (PMID:33144218) (PMCID:PMC7758710)

Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31(6), 107625. (doi: 10.1016/j.celrep.2020.107625) (PMID:32402285)

Dreyer, S.B., Jamieson, N.B. , Morton, J.P. , Sansom, O.J. , Biankin, A.V. and Chang, D.K. (2020) Pancreatic cancer: from genome discovery to PRECISION-Panc. Clinical Oncology, 32(1), pp. 5-8. (doi: 10.1016/j.clon.2019.08.007) (PMID:31522943)

Beer, P. A., Cooke, S. L. , Chang, D. K. and Biankin, A. V. (2019) Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice. Annals of Oncology, 30(11), pp. 1691-1694. (doi: 10.1093/annonc/mdz392) (PMID:31665210)

Tandon, M. et al. (2019) Prolactin promotes fibrosis and pancreatic cancer progression. Cancer Research, 79(20), pp. 5316-5327. (doi: 10.1158/0008-5472.CAN-18-3064) (PMID:31395607) (PMCID:PMC6801092)